IGI Logo

Granules India is currently trading at Rs. 310.65, up by 4.15 points or 1.35% from its previous closing of Rs. 306.50 on the BSE.

The scrip opened at Rs. 310.00 and has touched a high and low of Rs. 312.95 and Rs. 308.00 respectively. So far 31785 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 362.25 on 14-Jan-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 314.90 and Rs. 303.15 respectively. The current market cap of the company is Rs. 7697.08 crore.

The promoters holding in the company stood at 41.98%, while Institutions and Non-Institutions held 26.16% and 31.85% respectively.

Granules India has received approval from US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release (ER) Tablets, 600 mg/60 mg and 1200 mg/120 mg (OTC). It is bioequivalent to the reference listed drug product, Mucinex D Extended-Release Tablets, 600 mg/60 mg and 1200 mg/120 mg, of RB Health (US) LLC.

Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets are used to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, upper respiratory allergies; temporarily restores freer breathing through the nose; promotes nasal and/or sinus drainage; and temporarily relieves sinus congestion and pressure. Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).